Centrexion Therapeutics Corpis A Biopharmaceutical Company Based In Bostonmassachusettsfocused On Developing Non Opioidnon Addictive Therapies For Chronic Pain Managementwith A Team Of Approximately 24 Employeescentrexion Aims To Tackle The Chronic Pain Epidemic Affecting Millions Of People Globally The Company Utilizes Big Data Analytics And Innovative Clinical Trial Strategies To Identify Pain Pathwaystheir Pipeline Includes Several Clinical Stage Candidatessuch As Cntx 4975Which Targets Pain Sensing Nerve Fibers Through Direct Injectionand Cntx 0290An Investigational Small Molecule For Pain Modulationother Candidates Include Cntx 6970An Oral Ccr2 Antagonistand Cntx 2022A Topical Lidocaine Gel For Localized Pain Reliefcentrexion Employs Various Delivery Methods Tailored To Specific Pain Typesemphasizing Efficiency In Their Clinical Strategy Centrexion Is Dedicated To Reducing The Burden Of Chronic Painaddressing The Needs Of Patients With Moderate To Severe Conditions Like Osteoarthritis And Neuropathic Paintheir Mission Focuses On Improving Patient Outcomes And Reducing Healthcare Costs Associated With Long Term Pain Management
